

ASX ANNOUNCEMENT

Vitura settles dispute with Code4 Cannabis

17 OCTOBER 2024

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and Company**), a leading digital health platform business focused on innovating the delivery of healthcare by building a centralised healthcare experience, is pleased to announce that it has reached agreement to settle its dispute with software developer Code4 Cannabis Pty Ltd (**C4C**).

Pursuant to an agreement between the parties dated 16 October 2024 (**Settlement Agreement**), Vitura's wholly-owned subsidiary, Canview Pty Ltd (**Canview**), will, subject to completing to its satisfaction a short period of due diligence and certain other events as described below, acquire from C4C a complete copy of the software, data and all related materials underlying the Company's "Canview" platform (**Copy**). At that time, the Vitura group will withdraw all legal proceedings against C4C. This means that Vitura will own and operate its own copy of the Canview platform into perpetuity and take direct ownership of managing that copy of the platform.

Key Terms

- Subject to Canview completing to its satisfaction a short period of due diligence and certain other events as described below, Canview will acquire ownership of the Copy which will enable Vitura to establish the Canview platform in its own environment and operate and develop its Copy of the platform going forward.
- Pursuant to the Settlement Agreement, for a period of 90 days from the date on which the Copy is received, C4C is obligated to provide Canview with all support and information necessary to ensure the orderly and timely establishment of the Copy of the Canview platform in Vitura's environment and that the Copy is fully operational.
- Subject to an independent expert certifying that the Copy is fully operational (**Certification**), Vitura will pay to C4C an amount of \$2.5 million in cash and 5,787,037 ordinary shares in Vitura (being the equivalent of \$500,000 worth of Vitura ordinary shares at a price equal to the volume weighted average price of Vitura's shares for the five trading days immediately preceding the date of the Settlement Agreement, being \$0.0864 per share). Such shares will be issued within two business days of Certification being granted.
- Upon Certification, Canview will be granted property in the Copy enabling it to exploit, modify, use or otherwise deal with the Copy and an irrevocable licence to use, modify and sublicense the Copy. Canview will not, however, be able to sell further copies of the Copy to any third party for a period of 12 months from the date of the Settlement Agreement. Upon Certification, the Services Agreement between C4C and Canview, which is currently due to terminate in November 2025, will terminate immediately and the fees being paid to C4C by Canview, amounting to approximately \$100,000 per month, will cease.

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU





- Pursuant to the Settlement Agreement, C4C will be restrained from using, exploiting or dealing with the platform for a period nine months from the date of Certification and for a period of 12 months in the case of any party operating in the medicinal cannabis or nicotine industries.
- Finally, on Certification, Vitura and Canview will cease all current proceedings against C4C.

The settlement with C4C will enable Vitura to leverage its Copy of the platform as the base to rapidly expand its technology stack with less risk and in a far more cost-effective way, in line with the platform functionality required to deliver the Company's Strategy Reset.

In commenting on the agreement between C4C and the Company, Vitura's Independent Non-Executive Chairman Mr. Robert Iervasi said: "We are very pleased to be able to bring the dispute with C4C to an end and to be in a position where we will have complete control of the future operation and development of our market-leading Canview platform. This is an exceptional outcome for both parties. We are confident that, under the direction of our CTO Stefan Schmidt, we will be able to introduce a number of valuable new products and features on the platform that will excite our customers and further secure our position as a leading player in our space, enabling us to deliver on our Strategy Reset".

**** ENDS ****



About Vitura Health Limited (ASX: VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from roughly 60 international and domestic brands.
- www.canview.com.au
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,500 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

**Authorised by**

Robert Iervasi, Chair and Non-Executive Director

Contact**Vitura Health Limited**

Robert Iervasi

Chair

1300 799 491

info@vitura.com.au

Media enquiries

Rebecca Harrison

The Civic Partnership

+61 408 529 751

rebecca.harrison@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.